Rheumatoid arthritis vaccine DR4-1

Drug Profile

Rheumatoid arthritis vaccine DR4-1

Alternative Names: AnervaX.RA; RA-AnervaX

Latest Information Update: 15 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Corixa Corporation
  • Class Antirheumatics; Peptide vaccines; Peptides; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 14 Apr 2000 Corixa has received a US patent for AnervaX.RA™
  • 07 Feb 2000 AnervaX.RA™ is available for licensing worldwide (http://www.corixa.com)
  • 07 Feb 2000 Suspended-II for Rheumatoid arthritis in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top